Hematologic Oncology Update

Dr Joshua Richter from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, discusses the role of bispecific antibodies in multiple myeloma.

Drs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease.

Dr Ruben A Mesa from Wake Forest University School of Medicine in Winston-Salem, North Carolina, discusses recent updates on available and novel treatment strategies for myelofibrosis.

Dr Carlos de Castro, Prof Alexander Röth and Dr Ilene Weitz summarize the biology of paroxysmal nocturnal hemoglobinuria, current treatment approaches, and practical considerations for patients with the disease.

Dr Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center in Houston discusses updated findings from ASH 2023 on management approaches for myelofibrosis and polycythemia vera.

Dr Bita Fakhri from Stanford University in Stanford, California, discusses recent updates from ASH 2023 for the management of chronic lymphocytic leukemia and Richter’s syndrome.

Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma.

Dr Stephen T Oh from Washington University School of Medicine in St Louis, Missouri, discusses current and emerging monitoring and management strategies for myelofibrosis.

Dr Lindsey Roeker from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Jeff Sharman of the US Oncology Network in Eugene, Oregon, discuss relevant datasets from 2023 on the management of chronic lymphocytic leukemia.

Dr Richard M Stone from Dana-Farber Cancer Institute in Boston discusses the optimal selection and sequencing of systemic therapies for patients with acute myeloid leukemia and myelodysplastic syndromes.

Dr Gail J Roboz from Weill Cornell Medicine in New York discusses the optimal management of acute myeloid leukemia and myelodysplastic syndromes.

Dr Naval Daver from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging optimal management approaches for patients with acute myeloid leukemia and myelodysplastic syndromes.

Dr Toby A Eyre from the Oxford University Hospitals NHS Foundation Trust in Oxford, United Kingdom, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, discuss the management of relapsed/refractory mantle cell lymphoma.

Dr Joseph Mikhael from the City of Hope Cancer Center in Phoenix, Arizona, discusses recent updates and future directions in the management of newly diagnosed and relapsed/refractory multiple myeloma.

Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.

Prof Philippe Moreau from the University Hospital of Nantes in France discusses anti-CD38 antibody-based treatment approaches for newly diagnosed and relapsed/refractory multiple myeloma, moderated by Dr Neil Love.

Dr Naveen Pemmaraju from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging management approaches for blastic plasmacytoid dendritic cell neoplasms.

Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston discusses the emerging role of CELMoDs and other novel approaches to targeting protein degradation pathways in the treatment of multiple myeloma.

Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma.

Dr Martin Hutchings from Rigshospitalet, Copenhagen University Hospital in Copenhagen, Denmark, and Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.

Featuring a discussion on BTK inhibitors for the management of mantle cell lymphoma with Dr Michael Wang, moderated by Dr Neil Love.

Dr Richard F Riedel from Duke Cancer Institute in Durham, North Carolina, discusses approved and novel treatment approaches for soft tissue sarcoma, moderated by Dr Neil Love.

Dr Jeremy Abramson from Massachusetts General Hospital in Boston discusses key presentations on chronic lymphocytic leukemia and lymphomas from recent oncology/hematology conferences.

Dr Hans Lee from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York, New York, discuss approved and novel bispecific antibodies and their current and potential roles in the treatment of multiple myeloma.

Dr Kerry Rogers from the Ohio State University in Columbus, Ohio, discusses the education and care of patients with chronic lymphocytic leukemia